GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ADCT · Mar 31, 2026

ADC Therapeutics SA. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-26-029819General Corporate

Capex intensity22thOwn-history percentile · N=9

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.16% · OPTIONAL · VALID

Operating cash generation78thOwn-history percentile · N=9

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-148.31% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

15.11% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure22thOwn-history percentile · N=9

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

23.84% · OPTIONAL · VALID

Operating margin100thOwn-history percentile · N=9

Evidence method

Level · gp.fundamentals.operating_margin

-126.02% · CORE · VALID

R&D intensity0thOwn-history percentile · N=9

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

99.22% · OPTIONAL · VALID

SBC intensity56thOwn-history percentile · N=9

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

12.19% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History8 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20256/8 normalizedLevel 3 Mar 31, 20266/7 normalizedLevel 3 Jun 30, 20266/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 0.32%
Current: 0.16%
Delta: -0.16%

Cash Generation Increased

Previous: -173.52%
Current: -148.31%
Delta: 25.22%

Growth Increased

Previous: 14.85%
Current: 15.11%
Delta: 0.25%

Inventory Pressure Increased

Previous: 5.14%
Current: 23.84%
Delta: 18.70%

Profitability Increased

Previous: -149.34%
Current: -126.02%
Delta: 23.32%

R And D Intensity Decreased

Previous: 127.84%
Current: 99.22%
Delta: -28.62%

Sbc Intensity Increased

Previous: 8.49%
Current: 12.19%
Delta: 3.70%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ADCT Fundamental State →Has State · ADC Therapeutics SA →Transitioned To · ADCT Fundamental State →Transitioned To · ADCT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADCT CAPEX_INTENSITY_DECREASED →Transitioned To · ADCT CASH_GENERATION_INCREASED →Transitioned To · ADCT GROWTH_INCREASED →Transitioned To · ADCT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADCT PROFITABILITY_INCREASED →Transitioned To · ADCT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.